A method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER 1 /Human EGFR) comprising administering to a patient in need of such treatment a flexible and active regimen for combining a tyrosine kinase inhibitor (TKI) and anti EGF antibodies for inhibition of the pathway activated by EGF EGFR binding (mAb). The anti EGF antibodies can be produced by active immunization or provided passively by the administration of antibodies that are anti EGF. The method comprises TKI administered according to a continuous regimen based on an average daily dose in the range of 10 to 150 mg and the mAb is co administered either actively or passively according to a dosing regimen achieving a therapeutic effective amount repeated thrice twice or once a week once in two weeks once in three weeks or at least once monthly.
